NACFC 2025 | S12: PRenatal MOdulator Treatment to PrEvent Cystic Fibrosis ComplicaTions (PROTECT)

CFTR modulator use among pregnant women is increasing, including among individuals with CF, as well as those without CF but whose pregnancies have been diagnosed with CF. This session highlights updates on information shared at the Cystic Fibrosis Foundation’s PROTECT workshop, including data from CF animal models treated with CFTR modulators, updates on CFTR modulator safety in both pregnant people with and without CF, as well as a review of current U.S. and European case data. Members of the CF community also share their related experiences. Originally recorded Oct. 23, 2025. Recording may have been edited for time and/or content.